Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
This comprehensive course will enhance your understanding of hematopoietic stem cell transplant (HSCT) and provide concepts to apply to your care of HSCT patients.
When used in combination with fulvestrant, alpelisib (Piqray®) produced complete or partial responses in 29% of patients with PIK3CA-altered, estrogen receptor-positive advanced breast cancer in clinical trials. The U.S. Food and Drug Administration (FDA) approved it for use in 2019.
After clinical trials demonstrated a 25% response rate in patients with multiple myeloma, selinexor (Xpovio®) received initial, accelerated U.S. Food and Drug Administration approval in 2019.
This module, a part of the comprehensive Hematopoietic Stem Cell Transplantation course, provides an overview of graft-versus-host disease (GVHD), a common complication of stem cell transplant.
In May 2020, the U.S. Food and Drug Administration gave accelerated approval for selpercatinib (Retevmo®) to treat RET-altered non-small cell lung cancer (NSCLC) or thyroid cancer based on overall response rate and duration of response. Selpercatinib fights cancer by impeding RET protein activity. The determining clinical trial results demonstrated that it reduced tumor size in more than 50% of patients and was associated with fewer adverse reactions than other drugs that block the RET protein.
Intentional, facilitated conversations are opportunities for healthcare staff to gather outside of patient care, meetings with agendas, or formal conferences. The ability, time, and space to connect in a way that allows speaking with intention and listening with attention supports individual and team resilience.
Ribociclib (Kisqali®) is a CDK 4/6 inhibitor first approved by the U.S. Food and Drug Administration in early 2017 for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine therapy, based on the MONALEESA trial results.
In an open-label, multicenter, multicohort study that included 90 patients with relapsed or refractory follicular lymphoma who had received at least two prior lines of systemic therapy, 60% of patients receiving treatment with mosunetuzumab-axgb achieved a complete response and 80% had an overall response. On December 22, 2022, the U.S. Food and Drug Administration granted mosunetuzumab-axgb accelerated approval based on those findings.
With an estimated duration of response rate of 90.6% at six months and 66.5% at nine months in the agent’s clinical trials, in October 2022, the U.S. Food and Drug Administration granted accelerated approval to teclistamab-cqyv (Tecvayli™) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four previous lines of therapy.
After clinical trials demonstrated a 43% durable objective response rate with a median 8.5-month duration, the U.S. Food and Drug Administration (FDA) granted adagrasib (Krazati™) accelerated approval in December 2022 for adult patients with locally advanced or metastatic non-small cell lung cancer with a KRAS G12C variant, as detected by an FDA-approved test, whose disease has progressed on or after at least one prior systemic therapy.